Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 17 , ISSUE 1 ( January-February, 2025 ) > List of Articles

RESEARCH ARTICLE

Azithromycin as an Adjunct Prophylactic Drug for Prevention of Surgical Site Infection in Cesarean Delivery: A Randomized Controlled Trial

Yuktha Khanna, Gauri A Prabhu, Anita Dalal, Sudhanshu M Gan

Keywords : Azithromycin, Cesarean delivery, Surgical site infection

Citation Information : Khanna Y, Prabhu GA, Dalal A, Gan SM. Azithromycin as an Adjunct Prophylactic Drug for Prevention of Surgical Site Infection in Cesarean Delivery: A Randomized Controlled Trial. J South Asian Feder Obs Gynae 2025; 17 (1):29-33.

DOI: 10.5005/jp-journals-10006-2598

License: CC BY-NC 4.0

Published Online: 28-03-2025

Copyright Statement:  Copyright © 2025; The Author(s).


Abstract

Introduction: There has been a significant rise in cesarean section rates worldwide over the past two decades. Currently, cesarean section is responsible for almost 21% of all births, which is equivalent to nearly one birth out of every five women. A cesarean section is one of the most common surgical procedures that is associated with occurrence of surgical site infections. The purpose of this research is to study whether addition of azithromycin to standard antibiotic prophylaxis before skin incision would decrease the incidence of surgical site infection after cesarean section. Material and methods: The present study was conducted in the Department of Obstetrics and Gynecology, KLES Dr Prabhakar Kore Hospital and MRC, Belagavi from January 2023 to January 2024. Pregnant women at gestational age of 28 weeks or more, who are to undergo emergency cesarean delivery who have given informed consent, were recruited. Group A received the standard antibiotic prophylactic drug-injection, ceftriaxone 1 gm IV. Group B received the standard antibiotic prophylactic drug injection ceftriaxone 1 gm IV along with injection azithromycin 500 mg IV (given within 60 minutes prior to incision). The primary outcome of surgical site infection was studied and compared between two groups. Results: The incidence of surgical site infection in the control group was 35.9%. In the intervention group, the incidence was significantly less, i.e. 13.2% (p-value 0.001). Surgical site infections are categorized as superficial, deep, or organ space. In group A, there were 48 superficial infections (85.7%) and 8 deep infections (14.3%). There were 5 superficial infections (71.4%) and 2 deep infections (28.6%) in group B. In this study, mean postoperative stay was 5.72 days with a standard deviation of 1.617 in group A and 5.31 days with a standard deviation of 1.176 in group B. The mean postoperative stay was slightly shorter in group B, suggesting a potential benefit of azithromycin in reducing hospital stay duration. The proportion of readmissions was higher in group A, suggesting a potential benefit of azithromycin in reducing readmissions. Conclusion: In this randomized controlled trial conducted at our hospital involving 256 participants over a span of 1 year, it was concluded that adjunctive azithromycin administration decreases postoperative infectious morbidity in emergency cesarean deliveries when administered within 60 minutes prior to skin incision.


PDF Share
  1. Betran AP, Ye J, Moller AB, et al. Trends and projections of Switzerland section rates global and regional estimates. BMJ Glob Health 2021;6(6):e005671. DOI: 10.1136/bmjgh-2021-005671.
  2. Nivedita R, Kumar PK, Kumar V, et al. Changing scenario of cesarean section delivery in India. Journal of Family Medicine and Primary Care 2021;10(11):4182–4188. DOI: 10.4103/jfmpc.jfmpc_585_21.
  3. Ronald G. Clinical risk factors for puerperal infection. Obstet Gynecol 1980:55(3):178S–184S. DOI: 10.1097/00006250-198003001-00045.
  4. Ruzic MF, Christina TB, Gabriella DC, et al. Adjunctive azithromycin prophylaxis for prelabor cesarean birth. Obstet Gynecol 2023;141(2):403–413. DOI: 10.1097/AOG.0000000000005037.
  5. Tita ATN, Boggess K, Saade G. Adjunctive azithromycin prophylaxis for caesarean delivery. N Engl J Med 2017;376(2):182. DOI: 10.1056/NEJMc1614626.
  6. Liu R, Lin L, Wang D. Antimicrobial prophylaxis in caesarean section delivery. Exp Ther Med 2016;12(2):961–964. DOI: 10.3892/etm.2016.3350.
  7. Emmons SI, Krohn M, Jackson M, et al. Development of wound infections among women undergoing cesarean section. Obstet Gynecol 1988;72(4):559–564. PMID: 3419735.
  8. Roberts S, Maccato M, Faro S, et al. The microbiology of post caesarean wound morbidity. Obstet Gynecol 1993;81(3):383–386. PMID: 8437791.
  9. Huang D, Chen S, Cai Y, et al. Adjunctive azithromycin prophylaxis protects women from uterine cesarean scar defect: A randomized controlled trial. Acta Obstet Gynecol Scand 2022;101(8):889–900. DOI: 10.1111/aogs.14387.
  10. Smaill FM, Grivell RM. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. Cochrane Database Syst Rev 2014;2014(10):CD007482. DOI: 10.1002/14651858.CD007482.pub3.
  11. Costantine MM, Rahman M, Ghulmiyah L. Timing of perioperative antibiotics for cesarean delivery: A metaanalysis. Am J Obstet Gynecol 2008;199(3):301.e1–6. DOI: 10.1016/j.ajog.2008.06.077.
  12. Seibert J, Pena SR, Yelverton E, et al. 316: Implementation of an azithromycin protocol to decrease post-cesarean infections. American Journal of Obstetrics and Gynecology 2020;222(1S): S212–S213. DOI: 10.1016/j.ajog.2019.11.331
  13. Yang M, Yuan F, Guo Y, et al. Efficacy of adding azithromycin to antibiotic prophylaxis in caesarean delivery: A meta-analysis and systematic review. Int J Antimicrob Agents 2022;59(3):106533. DOI: 10.1016/j.ijantimicag.2022.106533.
  14. Ketcheson F, Woolcott C, Allen V, et al. Risk factors for surgical site infection following cesarean delivery: A retrospective cohort study. CMAJ Open 2017;5(3):E546–E556. DOI: 10.9778/cmajo.20160164.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.